Researchers and doctors from the AP-HP, the Institut Pasteur, the University of Paris and the Sorbonne University, have carried out work on the effect of immune checkpoint inhibitors (anti-PD1 and anti-CTLA4) on cellular immunity against SARS-CoV-2. This work, the results of which suggest that these treatments are not deleterious during infection with COVID-19 and, on the contrary, seem to improve the antiviral cellular immune response, were the subject of a publication within the journal  Science Advances.

Find out more